Jane Street’s SAB Biotherapeutics SABS Stock Holding History

Jane Street’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$39.4K	Buy	+10,300	New	+$41.1K	﹤0.01%	11043

Other funds holding SABS

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jane Street's SABS Position: Q4 2022 in Review

Jane Street sold out of SAB Biotherapeutics (SABS) in Q4 2022, closing a stake of 2,395 shares — an estimated $17K sold.

Jane Street first reported a position in SABS in Q1 2021 and held it in 4 quarters. The position peaked at $360K in Q3 2021. 38 funds tracked by Wall St. Rank hold SABS as of Q4 2022.

Jane Street reported no remaining SAB Biotherapeutics position as of Q4 2022 after selling out during the quarter.
Jane Street sold 2,395 SAB Biotherapeutics shares in Q4 2022, an estimated $17K.
Jane Street first reported a position in SAB Biotherapeutics in Q1 2021 and held it in 4 quarters.
Jane Street's SAB Biotherapeutics position peaked at $360K in Q3 2021.
38 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q4 2022.

Based on Jane Street's 13F filing for Q4 2022, filed 15 Feb 2023.